ArticleJournal of thoracic disease2009
Establishment of a lung cancer biobank of a southern chinese population.
Article in Journal of thoracic disease, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Lung cancer biobanking in Australia: challenges and future directions.The Medical journal of Australia · 2025Article
- Establishment and management of a lung cancer biobank in Eastern China.Thoracic cancer · 2015Article
- The expression and clinical significance of CLIC1 and HSP27 in lung adenocarcinoma.Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine · 2011Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
There is an increasing need for establishment of biobanks for human cancer, which may facilitate basic and clinical researches as well as the development of novel approaches to early diagnostics, prevention and treatment, including personalized medicine. Herein we report the establishment of a lung cancer biobanks using biological samples from a lung cancer patient population in Southern China. Since 2007, we have collected lung cancer tissue from 1,054 patients with lung cancer, from whom 11,895 frozen tumor and normal matched tissues, 4,899 tissue paraffin blocks, and 3,562 blood serum samples were accumulated. The information on clinical manifestations, laboratory tests, and follow-up was maintained by an independent information management system, including three data sets. The primary data set included frozen tissue specimens, formalin-fixed paraffin-embedded tissues, blood specimens and clinical and long-term follow-up data. The secondary data set included DNA, RNA and proteins extracted from corresponding tissue specimens. And the tertiary data set contained improved genome, RNA and proteomics correlation analysis with relevant clinical and long-term follow-up data. The lung cancer biobanks is accessible to academic research and public services. To our best knowledge, this biobanks represents the first lung cancer tissue reservoir in China and should facilitate the basic and clinical research of this disease and developing diagnostic markers and novel therapeutic modalities.
Indexed as
Identifiers
22262997PMC3256478What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.